Hong Kong & China Medical Device Regulatory Outsourcing

Mandatory in-country testing, the necessity for local legal representation, and the frequent updates to regulations and technical standards contribute to a highly intricate approval process. These requirements differ significantly from those in the U.S. or EU, making local expertise and assistance not just beneficial, but essential.

For medical device companies, this complexity emphasizes three critical priorities: accelerating time to market, ensuring full regulatory compliance, and controlling operational costs. Achieving all three internally is challenging, especially without a dedicated team on the ground in China. This is why outsourcing regulatory affairs to a specialist provider offers a strategic advantage.

Cisema assists international medical device companies with comprehensive regulatory affairs and compliance services specifically tailored to China. We help you register, launch, and maintain your products in full compliance with NMPA requirements, without the need to develop internal capabilities in China.

We function as your external regulatory department, managing every step from marketing authorizations to PMS. This allows you to stay compliant, competitive, and focused on your core business.

GMP Medical Devices
Outsourcing service

Benefits of Regulatory Affairs Outsourcing Services for China

Local Expertise with Global Integration

Cisema experts will guide you at every stage of product development, ensuring compliance, strategic alignment and a successful market entry. We facilitate interactions with regulatory agencies to streamline the approval process.  

Accelerated Access

By outsourcing regulatory tasks, companies can expedite approvals, seizing commercial opportunities more quickly and responding swiftly to demand.

Efficient

Eliminating the need for internal teams to manage complex regulations reduces overhead and enhances financial efficiency.

Concentration on Core Strengths

By delegating regulatory responsibilities, your internal teams can focus on innovation, production, and business growth, thereby boosting productivity.

Access to Specialized Knowledge

Partnering with an experienced regulatory outsourcing firm like Cisema grants you access to advanced regulatory strategies and technical expertise for efficient authorizations.

Enhanced Compliance & Risk Management

We assist in establishing robust quality systems, maintaining precise documentation, conducting audits, and ensuring adherence to NMPA standards — minimizing the risk of non-compliance.

Independent & Confidential Service

We operate solely on your behalf. As we are not a distributor, there is no conflict of interest, ensuring transparency and trust.

Our Regulatory Affairs Outsourcing Services

Our global presence, including offices in Europe, North America and Asia, allows us to provide a wide range of outsourcing services to medical device companies internationally. We understand the importance of regulatory compliance and quality management systems (QMS) for companies.

NMPA Approvals

Class I, II, and III medical devices
Local type testing, clinical evaluation, and dossier submission
Fast-track and innovative device pathways

Legal Agent & In-Country Representative

Act as your local agent with the NMPA
Maintain product licenses and regulatory compliance
Liaise with Chinese authorities on your behalf

Post-Market Surveillance

Adverse event reporting assistance
Change notifications and license renewals
UDI and tracking system support

Quality Management & Compliance

Compliance with Chinese GMP
Internal audits and documentation support
Risk management planning and implementation

Labeling & Packaging Compliance

Chinese Label and IFU review
UDI and barcode checks
Language and format verification

Regulatory Documentation & Control

Document control and quality system maintenance
Accurate, up-to-date documentation aligned with NMPA expectations

Training & Consultancy

Risk management and quality system training
Preparation for on-site inspections and supplier audits

Useful Articles

View More

Understanding Local Testing for Medical Devices & IVDs in Indonesia: Requirements & Registration Guide

Learn when local testing is required for medical devices and IVDs in Indonesia, which products are affected, and how testing impacts registration requirements.

August 31, 2026
Understanding Local Testing for Medical Devices & IVDs in Indonesia: Requirements & Registration Guide
An Indonesian male medical professional in profile, wearing dark blue scrubs, a blue surgical cap, safety glasses, a white mask, and a blue-tubed stethoscope, presses a button on a dual-monitor medical control panel in a clinical operating setting.

China Medical Device GMP vs ISO 13485: Key Differences Explained

Understand the key differences between China Medical Device GMP and ISO 13485, including requirements for quality management, suppliers, facilities and documentation.

August 26, 2026
China Medical Device GMP vs ISO 13485: Key Differences Explained
Two Chinese medical device technicians, a woman and a man wearing white lab coats, surgical caps, face masks, and protective gloves, stand side by side in a sterile cleanroom environment.

5-Step Guide to Taiwan Medical Device Classification (TFDA)

How to determine medical device classification in Taiwan: the TFDA catalogue, the 16 categories, Class I-III risk levels, and what to do when no item matches.

August 21, 2026
5-Step Guide to Taiwan Medical Device Classification (TFDA)

Guide to Indonesia Medical Device Post-Registration Changes: Notification, Variation, or New Registration

Learn when medical device and IVD changes in Indonesia require a notification, variation, or new registration, and how to maintain ongoing regulatory compliance.

August 5, 2026
Guide to Indonesia Medical Device Post-Registration Changes: Notification, Variation, or New Registration

How Vietnam Medical Device Registration Works (Timelines, Fees, & AR Strategy)

Gain an overview of the medical device registration process in Vietnam with timelines, fees, and Authorized Representative requirements.

August 4, 2026
How Vietnam Medical Device Registration Works (Timelines, Fees, & AR Strategy)

Understanding the ASEAN Medical Device Market: Comparing 6 Strategic Markets

Explore the medical device market opportunities, regulations, and registration pathways across Malaysia, Singapore, Vietnam, and other key ASEAN countries.

August 4, 2026
Understanding the ASEAN Medical Device Market: Comparing 6 Strategic Markets
Previous
Previous

Explore Related Services

Whether you’re just starting out or are a blue-chip, access our wide range of services and 
outsourcing solutions to help your business thrive.

China Medical Device Approvals

We guide you through every step of the China medical device registration and filing process. We take care of compliance with NMPA requirements, advising you on the optimal China entry pathway, and helping you through the whole process.

Learn more

NMPA Legal Agent

We are your authorized representative in China, and fulfill your registrations and filings as well as ensuring compliance with quality and PMS requirements.

Learn more

China Clinical Trials

You may be required to provide supplementary clinical data on Chinese patients or conduct a full clinical trial in China.Our clinical research team will advise you, prepare the study protocol and assist setting up the clinical trial in China.

Learn more

NMPA Type Testing

Our on-site test engineers coordinate and supervise type tests of your medical devices in NMPA-accredited laboratories.

Learn more

Drug Device Combination Products

We assist with the classification, authorization, and compliance of combination products in China, whether drug or device led.

Learn more

China Medical Device Quality Compliance

We help you achieve and ensure ongoing compliance with Chinese requirements.Our experts prepare and assist you for official NMPA inspections.

Learn more

Medical Device PMS & Vigilance

The NMPA is placing greater focus on PMS such as more in-China sampling inspections and regular standard changes.Our specialist PMS team means you stay up to date with the many aspects of compliance.

Learn more

NMPA Clinical Evaluation Report

Clinical Evaluation Reports can avoid the need for a China clinical trial in some instances. Our experts can advise and prepare NMPA compliant CERs.

Learn more

Latest Insights

View More

Malaysia NPRA Updates Cosmetic Ingredient Requirements Under the ASEAN Cosmetic Directive

Circular No. 2/2026 revises prohibited, restricted, colorant, and preservative requirements for cosmetics marketed in Malaysia.

August 20, 2026
Malaysia NPRA Updates Cosmetic Ingredient Requirements Under the ASEAN Cosmetic Directive

China Overhauls Cosmetic Safety Rules with GB 7916-2026: Is Your Brand Ready?

Brands must audit ingredients, suppliers and packaging before January 2028 to ensure compliance with GB 7916-2026.

August 18, 2026
China Overhauls Cosmetic Safety Rules with GB 7916-2026: Is Your Brand Ready?
Scientist in clean modern room inspects cosmetics.

China Expands Animal Testing Data Exemptions in Major Cosmetics Registration and Filing Reform

Companies can benefit from expanded toxicology data exemptions, simplified cosmetics registration procedures, and more efficient compliance pathways

August 18, 2026
China Expands Animal Testing Data Exemptions in Major Cosmetics Registration and Filing Reform

Taiwan Extends Cosmetic GMP Requirements to Nearly All Manufacturing Sites

As of July 1, 2026, Taiwan has completed its cosmetic GMP rollout, extending mandatory ISO 22716-based manufacturing standards to nearly all cosmetic factories

August 18, 2026
Taiwan Extends Cosmetic GMP Requirements to Nearly All Manufacturing Sites

China Updates New Cosmetic Ingredient Registration Rules: Several Higher-Risk Ingredient Categories Removed

New NCI rules reduce administrative burden, streamline dossiers, and expand opportunities to reuse existing safety data.

August 18, 2026
China Updates New Cosmetic Ingredient Registration Rules: Several Higher-Risk Ingredient Categories Removed
This stock photo features a close-up, high-angle shot focusing on a skincare product arrangement set against a light-colored, wood-grain surface.

NMPA Opens Consultation on Two Draft Cosmetic Adverse Reaction Standards: Cosmetic Cheilitis & Cosmetic Contact Urticaria

Review China's new draft standards for cosmetic cheilitis and contact urticaria before the August 15, 2026, consultation deadline.

August 18, 2026
NMPA Opens Consultation on Two Draft Cosmetic Adverse Reaction Standards: Cosmetic Cheilitis & Cosmetic Contact Urticaria
Previous
Previous

A Reliable Partner from Start to Finish

With over 20 years of experience and a proven track record, Cisema is trusted by startups and global medtech leaders alike to manage China regulatory affairs with efficiency and precision. Contact us today to discuss how we can support your China strategy.

Request Proposal